HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma

• ≥18 years
• Signed informed consent
• Patients with platinum-sensitive recurrence after 12-48 months after platinum-based firstline-chemotherapy of histological saved epithelial ovarian carcinoma, primary peritoneal carcinoma or tube carcinoma with planned cytoreductive operation
• The following histological types can be included: serous, endometrioide, clear cell or undifferentiated carcinoma. Mixed epithelial carcinoma, malignant Brenner Tumour
• No preceding recurrence chemotherapy
• Preceding hormontherapy admitted. Concomitant antineoplastic antihormone-therapy (Tamoxifen, Aromataseinhibitoren etc.) not admitted. Low dosed (physiological) hormone-replacement-therapie (HRT) can be administered
• Patients with maintenance therapy (e.g. Bevacizumab) permitted, assumed recurrence was diagnosed 12 months after primary cytotoxic chemotherapy (also with maintenancetherapy during chemotherapy) and last administration of maintenancetherapy happened min. 21 days before first study protocol intervention
• Resectability R0 probably, fixed by Desktop II-criteria:
• Cytoreductive operation at first-diagnosis of the carcinoma R0
• Ascites \<500 ml
• ECOG 0
• R0 status (≤0,5 cm tumour rest) at the end of secondary cytoreductive operation
• Eligibility for Standard systemic platinum-based combination chemotherapy after sec. cytoreductive operation with or without HIPEC (investigators decision)
• Bone marrow function: Haemoglobine ≥8.5 g/dL, Absol. neutrophile Granulocytes(ANC) ≥1.000/mm3, Thrombocytes ≥ 100.000/mm3
• Renal function: Serum Creatinin ≤1,5 times the ULN, calculated Creatininclearance (GFR) ≥60ml/min
• Liver function: Bilirubin ≤1,5 x
• ALT, AST ≤3 x ULN
• Adequate coagulation parameter: INR-value ≤1,5, aPTT ≤1,5 x ULN
• For patients under fully-dosed/therapeutic Warfarin- or Phenprocoumontherapy INR between 2-3 and aPTT \<1,2 x ULN
• Neurol. Function: peripheral Neuropathy ≤Grade 2 (CTCAE v4.03 criteria)
• In women with childbearing potential availability of a neg. serum pregnancy test 2 weeks before planned sec. cytored. operation + effective contraception during study period guaranteed

Exclusion Criteria:

• No signed informed consent
• Tumours with low malignant potential (Borderline-carzinomas)
• Patients with preceding radiotherapy in abdomen and pelvis
• Patients with preceding endometrial carcinoma will be excluded, except: Stage IA [no low differentiated subtype (serous-papillary, clear cellular, FIGO grade 3)]
• With the exception of non-melanoma skin cancer and other specific malignancies as noted above, subjects with other invasive malignancies, who had any evidence of the other cancer present within the last 3 years or whose previous cancer treatment contraindicates this protocol therapy, are excluded
• Known acute hepatitis
• acute infectious disease with need for intravenous antibiosis
• immunodeficiency
• Active coronaryarterial disease: Myocardinfarct or instable Angina pectoris within 6 months before study inclusion: coronary artery disease in anamnesis can be included, assumed a normal stress-electrocardiogram finding within 30 days before study inclusion
• Cardiac insufficiency NYHA ≥2 classif. of New York Heart Association
• Hypertension ≥140/90 mm Hg
• Poorly controlled cardiac arrythmia despite medication (patients with frequencey-controlled atrial fibrillation can participate)
• Peripheral vascular disease ≥grade 3 (e.g. symptomatic and affecting activities of everyday-life, intervention or revision necessary)
• Renal insufficiency Serumcreatininvalues ≥1,5 times the ULN or GFR \<60ml/min
• Cerebrovascular disease in anamnesis
• Patients with another severe medical problem-independent of cancer-which excludes study participation
• Known allergies to Carboplatin or Cisplatin
• extended intraperitoneal adhesions at time of secondary cytoreductive operation, which makes administration of intraperitioneal chemotherapy impossible
• Life expectancy \<12 weeks